Core Viewpoint - Guizhou Yibai Pharmaceutical Co., Ltd. has received a suspension notice from the Guizhou Provincial Drug Administration regarding the production and sale of its children's cough syrup due to regulatory non-compliance identified during an inspection by the National Medical Products Administration [1][2]. Summary by Sections Regulatory Action - The company was issued a suspension notice (No. 4 of 2025) due to deficiencies found during an inspection, including incomplete record-keeping and unreliable electronic data recording [1]. - The suspension is in accordance with the relevant regulations and is effective immediately upon receipt of the notice [1]. Financial Impact - The revenue from the children's cough syrup for the years 2021, 2022, 2023, and 2024 was reported as 3.42 million, 4.32 million, 8.38 million, and 1.51 million respectively, representing a small percentage of the company's total revenue at 0.10%, 0.16%, 0.30%, and 0.07% [2]. - The suspension of the children's cough syrup production and sales is not expected to have a significant impact on the company's overall performance [2].

Core Viewpoint - Guizhou Yibai Pharmaceutical has been ordered to suspend the production and sale of its children's cough syrup due to regulatory non-compliance, which is expected to have a minimal impact on the company's overall performance [1] Group 1: Regulatory Actions - On August 5, Guizhou Yibai Pharmaceutical received a notice from the Guizhou Provincial Drug Administration to immediately suspend the production and sale of its children's cough syrup [1] - The suspension was prompted by findings from the National Medical Products Administration indicating that the company had issues with record-keeping and data reliability [1] Group 2: Financial Impact - The children's cough syrup has contributed a small portion of the company's revenue, with sales figures of 3.42 million yuan, 4.32 million yuan, 8.38 million yuan, and 1.51 million yuan from 2021 to 2024, representing 0.10%, 0.16%, 0.30%, and 0.07% of total revenue respectively [1] - The company stated that the suspension is not expected to significantly affect its financial performance [1] Group 3: Recent Financial Performance - Guizhou Yibai Pharmaceutical projected a net loss of approximately 17.7 million to 21.24 million yuan for the first half of 2025, with a larger loss when excluding non-recurring items [4] - The company reported a 22.92% decline in total revenue for 2024, amounting to 2.174 billion yuan, and a net loss of 317 million yuan, a significant drop of 406.79% year-on-year [4] - The company has faced scrutiny from the Shanghai Stock Exchange due to accounting errors in its financial statements from 2017 to the first quarter of 2024, leading to restatements of prior financial data [5]

Shareholder Reduction - Chengdu Dijing and Zhuo Yuqing, shareholders of Ruidi Zhichu, plan to reduce their holdings by a total of no more than 2.52% [1] - Tongde Industrial, a shareholder of Foster, intends to reduce its holdings by no more than 32.5236 million shares [1] - Huizhou Junqiang, a shareholder of Green Precision, plans to reduce its holdings by no more than 1.238 million shares [1] - The National Integrated Circuit Fund, a shareholder of Debang Technology, plans to reduce its holdings by no more than 3% [1] - Zhang Lixin, chairman and core technical personnel of Chipeng Micro, intends to reduce his holdings by no more than 2.6262 million shares [1] - Qian Chunbo, director and deputy general manager of Chuhai Technology, plans to reduce his holdings by no more than 548,300 shares [1] - Tai'an Tai, a shareholder of Zhejiang Agricultural Shares, intends to reduce its holdings by no more than 3% [1] - UCM, a shareholder of Youde Precision, plans to reduce its holdings by no more than 1% [1] - Ruizhong Life Insurance, a shareholder of Tongzhou Electronics, intends to reduce its holdings by no more than 1% [1] - Guangdong Kechuang, a shareholder of Hongqiang Shares, plans to reduce its holdings by no more than 1% [1] Other Company News - Yibai Pharmaceutical received a "suspension of production and sales notice" from the Guizhou Provincial Drug Supervision Administration [1] - Zhongma Transmission is not involved in the robotics business [1]

Group 1: Import Drug Tariffs - The U.S. President Trump announced plans to impose "small tariffs" on imported drugs, with rates expected to rise to 150% within a year and potentially to 250% thereafter, aiming to encourage domestic production of pharmaceuticals [1] Group 2: National Drug Procurement - The National Healthcare Security Administration reported that 480 companies submitted information for the 11th batch of drug procurement, with an average of 15 companies per drug, and some drugs having over 40 companies competing [2] Group 3: Dongyangguang Changjiang Pharmaceutical - Dongyangguang Changjiang Pharmaceutical voluntarily withdrew its H-share listing in Hong Kong, as its parent company proposed a privatization plan to merge the company, which is expected to enhance operational efficiency and market performance post-merger [3] Group 4: Yibai Pharmaceutical - Yibai Pharmaceutical received a suspension notice from the Guizhou Provincial Drug Administration due to compliance issues found during inspections, specifically related to record-keeping and data reliability [4] Group 5: Lianhuan Pharmaceutical - Lianhuan Pharmaceutical responded to inquiries regarding unusual stock price fluctuations, stating there are no undisclosed significant matters affecting its stock price, and that its LH-1801 project is still in the research phase, which will not significantly impact revenue in the near term [5]

Macro News - The State Council issued opinions on gradually promoting free preschool education, stating that from the fall semester of 2025, public kindergarten tuition fees for the last year will be waived [1] - Seven departments, including the central bank, jointly issued guidelines to support new industrialization, aiming for a mature financial system for high-end, intelligent, and green manufacturing by 2027 [1] - The National Health Commission and 16 departments released an implementation plan for the "Healthy China Action - Healthy Environment Promotion Action (2025-2030)", with goals to improve drinking water quality and health literacy by 2030 [1] - Regulatory authorities are intensifying efforts to combat market fraud by punishing third-party companies that assist in fraudulent activities for listed companies [1] Industry News - The China Electromechanical Products Import and Export Chamber urged photovoltaic companies to adhere to fair competition principles and control capacity expansion according to global market demand [2] - Trump announced plans to impose drug tariffs, starting small but potentially reaching 250% [2] - The Guizhou Provincial Market Supervision Administration held discussions with travel platform companies to enforce compliance with laws and maintain a fair market environment [2] Company News - Upstream New Materials announced that it may apply for a continuous suspension of trading if its stock price continues to rise [6] - The Shanghai Stock Exchange reported abnormal trading behaviors affecting market order related to Upstream New Materials, leading to account trading suspensions for certain investors [6] Global Market - Major US stock indices closed lower, with the Dow down 0.14%, Nasdaq down 0.65%, and S&P 500 down 0.49% [7] - WTI crude oil futures fell by 1.7% to $65.16 per barrel, while Brent crude oil futures dropped by 1.63% to $67.64 per barrel [8] - COMEX gold futures rose by 0.25% to $3435 per ounce, and silver futures increased by 1.36% to $37.835 per ounce [9] New Stock Information - New stock HanSang Technology (301491) has an issue price of 28.91 with a PE ratio of 14.90, focusing on high-end audio products and solutions [10]

Group 1 - The company received a suspension notice from the Guizhou Provincial Drug Administration, requiring an immediate halt to the production and sale of its children's cough syrup due to regulatory non-compliance [1][2] - The suspension was based on findings from an inspection by the National Medical Products Administration, which identified deficiencies in record-keeping and data reliability [1][2] - The children's cough syrup generated revenues of 3.42 million, 4.32 million, 8.38 million, and 1.51 million yuan in 2021, 2022, 2023, and 2024 respectively, accounting for 0.10%, 0.16%, 0.30%, and 0.07% of the company's total revenue, indicating a relatively small impact on overall performance [2] Group 2 - The controlling shareholder, Dou Qiling, holds 185,457,636 shares, representing 23.42% of the total share capital, and has released part of the pledged shares [5][6] - After the release of the pledge, Dou Qiling has a total of 64,560,000 shares pledged, which is 34.81% of her holdings and 8.15% of the company's total shares [6] - The company will fulfill its disclosure obligations if the released shares are used for other pledge activities in the future [6]

新京报贝壳财经讯（记者丁爽）8月5日，益佰制药发布公告表示，公司近日收到贵州省药品监督管理局 出具的《暂停生产、销售通知书》。在国家药品监督管理局食品药品审核查验中心开展的检查工作中， 发现公司存在缺陷，涉及个别记录企业未如实填写，部分电子数据未能采用可靠的方式进行记录。经国 家药监局核查中心综合评定，结论为不符合。 《暂停生产、销售通知书》指出，根据国家药监局药品监管司《关于对贵州益佰制药股份有限公司有关 问题调查处理的通知》要求，结合《贵州省药品监督管理局药品安全隐患风险控制措施执行规则》第七 条中暂停生产、销售的情形，按照《药品检查管理办法（试行）》第六十一条之规定，现通知公司自收 到本通知后立即暂停小儿止咳糖浆生产、销售。 针对相关产品暂停生产带来的影响，公司表示，小儿止咳糖浆2021年-2024年的营业收入分别为342万 元、432万元、838万元、151万元，占公司当期合并报表营业收入的比例分别为0.10%、0.16%、 0.30%、0.07%，收入占比较小。本次小儿止咳糖浆暂停生产、销售预计不会对公司业绩产生较大影 响。 （文章来源：新京报） ...

针对相关产品暂停生产带来的影响，公司表示，小儿止咳糖浆2021年-2024年的营业收入分别为342万 元、432万元、838万元、151万元，占公司当期合并报表营业收入的比例分别为0.10%、0.16%、 0.30%、0.07%，收入占比较小。本次小儿止咳糖浆暂停生产、销售预计不会对公司业绩产生较大影 响。 编辑 陈莉 校对 付春愔 新京报贝壳财经讯（记者丁爽）8月5日，益佰制药发布公告表示，公司近日收到贵州省药品监督管理局 出具的《暂停生产、销售通知书》。在国家药品监督管理局食品药品审核查验中心开展的检查工作中， 发现公司存在缺陷，涉及个别记录企业未如实填写，部分电子数据未能采用可靠的方式进行记录。经国 家药监局核查中心综合评定，结论为不符合。 《暂停生产、销售通知书》指出，根据国家药监局药品监管司《关于对贵州益佰制药股份有限公司有关 问题调查处理的通知》要求，结合《贵州省药品监督管理局药品安全隐患风险控制措施执行规则》第七 条中暂停生产、销售的情形，按照《药品检查管理办法（试行）》第六十一条之规定，现通知公司自收 到本通知后立即暂停小儿止咳糖浆生产、销售。 ...

每经记者｜范芊芊 每经编辑｜董兴生 并购重组 嵘泰股份：拟以2.88亿元收购中山澳多51%股权 嵘泰股份公告称，公司拟使用自有资金2.88亿元收购中山市澳多电子科技有限公司（以下简称"中山澳 多"）51%股权，交易完成后，中山澳多将成为公司的控股子公司。本次交易构成关联交易，不构成重 大资产重组。交易价格以专业独立的第三方资产评估机构的评估价值为定价依据，并经双方协商一致确 定。 钧崴电子：全资子公司拟以26亿日元收购Flat Electronics Co.,Ltd.100%股权 海光信息：上半年归母净利润12.01亿元，同比增长41% 海光信息公告称，2025年上半年营业收入54.64亿元，同比增长45.21%；归母净利润12.01亿元，同比增 长40.78%。 东睦股份：上半年归母净利润为2.61亿元，同比增长37.61% 东睦股份公告称，上半年营业收入为29.30亿元，同比增长24.51%；归母净利润为2.61亿元，同比增长 37.61%。 中科曙光：上半年归母净利润同比增长29.89% 中科曙光发布业绩快报，上半年营业总收入为58.54亿元，同比增长2.49%；归属于上市公司股东的净利 润为7.31亿 ...

北京商报讯（记者 丁宁）8月5日晚间，益佰制药（600594）发布公告称，近日，公司收到贵州省药品 监督管理局出具的《暂停生产、销售通知书》。 益佰制药表示，公司产品小儿止咳糖浆2021—2024年的营业收入分别为342万元、432万元、838万元、 151万元，占公司当期合并报表营业收入的比例分别为0.1%、0.16%、0.3%、0.07%，收入占比较小。本 次小儿止咳糖浆暂停生产、销售预计不会对公司业绩产生较大影响。 贵州省药品监督管理局表示，在国家药品监督管理局食品药品审核查验中心开展的检查工作中，发现益 佰制药存在缺陷，涉及个别记录企业未如实填写，部分电子数据未能采用可靠的方式进行记录。经国家 药监局核查中心综合评定，结论为不符合。根据国家药监局药品监管司《关于对贵州益佰制药股份有限 公司有关问题调查处理的通知》要求，结合《贵州省药品监督管理局药品安全隐患风险控制措施执行规 则》第七条中暂停生产、销售的情形，按照《药品检查管理办法（试行）》第六十一条之规定，益佰制 药自收到通知后立即暂停小儿止咳糖浆生产、销售。 ...